Product Images Topiramate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Topiramate NDC 70518-2391 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Topiramate is a medication that is available in a pack of 30 HD3. It is a prescription drug and is manufactured by Cipla USA, Inc., Miami. The medication should be kept out of the reach of children and must be stored at temperatures between 20-26°C. The directions for use are available in the package insert. The medication has been repackaged by RemedyRepack Inc., Indiana.*
Topiramate is a prescription drug that is provided in a single HD3 quantity. It is NDC# 70518-2391-01 and is only available with a doctor's prescription. The drug has been manufactured by Cipla USA, Inc., located in Miami, FL 33156. The package insert contains guidelines for usage and should be followed carefully. The drug should be stored between 20-26°C (63-77°F) but can be kept at temperatures between 15-30°C (59-86°F) [See USP]. RemedyRepack Inc., located in Indiana, PA 15701, 724.466.8762 has repackaged the drug, and it should be kept out of the reach of children.*
Topiramate is a prescription drug that comes in a pack of 30 HD3 pills. The medication is manufactured by Cipla USA, Inc., Miami, FL 33156 and repackaged by RemedyRepack Inc., Indiana, PA 15701. The NDC number for this medication is 70518-2391-02 and the source NDC is 63097-0125-15. The expiration date and lot number are not available. The medication should be stored at 20-26°C (63-77°F) with excursions permitted to 15-30°C (59-86°F) [See USP]. Directions for use should be obtained from the package insert. Keep this and all medication out of the reach of children.*
This appears to be a graph showing cumulative rates for time to first seizure in relation to Topiramate dosage over a period of time, with the dosages being 50mg/day and 400mg/day. The graph plots time (in days) on the x-axis and cumulative rates on the y-axis.*
The text describes the change in the average monthly migraine period rate during a double-blind study phase for two different doses of a medication called TOPAMAX. The doses were 100 and 200 milligrams per day. The results showed a significant decrease in migraine frequency, with the higher dose demonstrating a greater reduction. The statistical significance of the findings is also indicated by the p-values.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.